Trial Profile
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2024 Results published in the Oncologist
- 16 Sep 2022 Status changed from active, no longer recruiting to completed, according to according ClinicalTrials.gov record.
- 14 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.